IRA Drug Pricing Implementation and PBM Reform Both on CMS Agenda, Pressuring CVS and UnitedHealth
CMS is simultaneously advancing Inflation Reduction Act drug price negotiation implementation and pharmacy benefit manager reform, creating a dual regulatory headwind for companies operating PBM businesses.
What CMS is working on simultaneously
The Centers for Medicare and Medicaid Services is pursuing two distinct but related drug-cost initiatives in parallel. First, it is implementing the existing Inflation Reduction Act drug price negotiation framework, including the first round of negotiated prices taking effect in 2026. Second, it is working on pharmacy benefit manager reform, targeting the business model of the middlemen who sit between drug manufacturers and pharmacies in the US drug distribution chain.
The two initiatives affect different parts of the healthcare value chain. The IRA drug price negotiation primarily affects pharmaceutical manufacturers by capping what Medicare pays them. PBM reform primarily affects PBM operators, targeting practices such as spread pricing, where PBMs pay pharmacies less than they charge insurers, and rebate arrangements that critics argue inflate list prices.
Why PBM reform is a specific risk for CVS and UnitedHealth
The two largest PBM operators are subsidiaries of US health-insurance conglomerates. CVS Health operates Caremark, one of the three largest PBMs in the country. UnitedHealth Group operates Optum Rx. Both companies derive significant revenue from PBM services, including drug rebate processing, formulary management, and specialty pharmacy.
Drug-pricing reform that targets PBM spread pricing or rebate arrangements would compress the revenue margin on these businesses. A requirement to pass through rebates to patients or payers, a transparency mandate, or a direct cap on spread pricing would reduce the economics of Caremark and Optum Rx relative to current operations.
Which stocks face the most direct impact
CVS Health is among the most directly exposed US headline companies. Its Caremark PBM is a central part of its integrated pharmacy-and-insurance model. Any PBM reform that reduces spread-pricing revenue or rebate income hits CVS's earnings from this segment directly.
UnitedHealth Group faces parallel risk through its Optum Rx PBM. Optum is UnitedHealth's fastest-growing and highest-margin division; PBM reform that pressures Optum's PBM economics has a material effect on the overall conglomerate's earnings outlook.
Eli Lilly faces the IRA implementation side. Mounjaro and Zepbound are approaching Medicare spend thresholds that trigger drug negotiation eligibility. Accelerated IRA implementation adds certainty to the timeline on which Lilly's flagship GLP-1 drugs will face price constraints in Medicare.
What to watch
For PBM reform, the key watchpoint is whether CMS advances a rule that includes a direct ban on spread pricing or mandates pass-through of rebates to plan members. For the IRA side, the publication of the 2026 negotiated prices and any court rulings on outstanding pharmaceutical industry legal challenges are the near-term catalysts.
Sources
Frequently asked questions
What is a pharmacy benefit manager, and why does reform threaten their business?
A PBM negotiates drug prices and manages drug formularies for insurance plans. Reform proposals target spread pricing and rebate arrangements that critics say add cost to the system without benefiting patients.
How are CVS and UnitedHealth exposed to PBM reform?
CVS operates Caremark and UnitedHealth operates Optum Rx, two of the three largest PBMs in the United States. Both businesses earn revenue from drug rebate processing and spread pricing that could be reduced under reform rules.
Is the IRA drug-pricing program the same as PBM reform?
No. The IRA program allows Medicare to negotiate prices directly with manufacturers. PBM reform targets the intermediaries who distribute those drugs, aiming to change how rebates and spreads flow through the supply chain.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track CVS free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.
Follow all 3 stocks in this story as one aggregated read with Pro.